top of page

A botulinum toxin type A injectable, similar in mechanism to Botox, Dysport, and Xeomin—relaxing targeted facial muscles to soften wrinkles .
Developed by Daewoong Pharmaceutical (South Korea) and FDA-approved in 2019 under the name Jeuveau .

⏱ Efficacy & Onset

Clinical trials show 85% of patients experienced improved glabellar frown lines within two days—faster onset than Botox .
Effects typically begin in 2–3 days, peak around two weeks, and last 3–4 months .

Nabota (Botulinum Toxin Type A)

$0.00

Quantity

Side Effects & Safety

Common side effects: bruising, swelling, injection-site pain, headache, temporary muscle weakness, and flu-like symptoms .

Rare but serious reactions: allergic responses, difficulty breathing/swallowing, or vision changes—seek medical attention if these occur ().

In professional use, proper technique and aftercare (avoid pressure, stay upright for 4 hours, avoid strenuous activity) reduce risks

bottom of page